Senior Consultant, BMT, Haematology & Paediatric Haemato-Oncology, Artemis Hospitals, Gurugram
Part 7 of 11 in Diagnosis and Management of Sickle Cell Disease
Bone Marrow Transplant for Sickle Cell Disease: Indications and Process
November 9, 2025
Bone marrow transplant has been recognised as a potential cure for sickle cell disease since a patient treated for acute leukaemia in the twentieth century was unexpectedly cured of sickle cell disease at the same time. It remains, in Dr. Gupta's words, the only mature, decades-proven curative therapy available today. Despite the name, it is a non-surgical, entirely medical procedure with no cutting involved.
When transplant is indicated
A history of stroke is an absolute indication. Two or more episodes of acute chest syndrome, transfusion dependence, more than three painful crises requiring hospital visits in a year, and screening evidence of cardiomyopathy or tricuspid valve regurgitation are all indications for transplant. Where there is a strong family history and a full-match donor is available, transplant is often pursued even with fewer symptoms, since success rates are highest at a younger age with well-preserved organ function.
How the transplant actually works
The donor receives four days of stem cell mobilising injections, and the stem cells are then collected from the donor's blood, not the bone marrow itself, and stored. The patient undergoes chemotherapy intense enough to destroy their own bone-marrow-forming capacity, and the stored donor stem cells are then infused through a vein, much like a standard blood transfusion. The most delicate step is engraftment, when the donor cells travel to the patient's bone marrow and begin producing healthy blood cells, usually within two to three weeks depending on the intensity of the conditioning regimen; every transplant physician stays alert until engraftment is confirmed.
This article is based on a Jivo Masterclass session conducted by Dr. Sukriti Gupta, Senior Consultant, BMT, Haematology and Paediatric Haemato-Oncology, Artemis Hospitals, Gurugram. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording
Looking for a haematology consultation or a second opinion? Get in touch with the Jivo team
This guide is based on a live Jivo Masterclass — Dr. Sukriti Gupta taught doctors across Africa on November 9, 2025.
FROM THE LIVE Q&A
Dr. Abraham
In terms of treatment, how is gene therapy done, and is it possible for all patients?
Dr. Sukriti Gupta
Gene therapy uses the patient's own stem cells rather than a donor, mobilised and collected the same way as for a transplant, then modified in a laboratory using either a viral vector for gene addition or CRISPR-Cas9 editing to correct the underlying genetic change, a process that currently takes around six months. Because the cells being returned are the patient's own, recovery is generally faster than with a donor transplant, but the therapy currently has FDA approval only for patients aged 12 and older, and it remains expensive and not yet widely available outside the US, Europe and a handful of other countries.
Book a Consultation with Dr. Sukriti Gupta
Book on WhatsAppOr message us on WhatsApp: +91 98182 98669
Frequently Asked Questions
In developing countries where finances are a barrier for most families, would you recommend gene therapy or bone marrow transplant?▼
If finances are genuinely not a barrier, gene therapy is worth choosing once it is better established, since it avoids the donor-related risks. But where finances are a limiting factor, an experienced allogeneic bone marrow transplant programme should still be trusted: it has decades of mature outcome data behind it, and families should not exhaust all their resources chasing a gene therapy process that could stall partway through. If a patient is having an acute crisis such as a recent stroke, there is also often not enough time to wait the six to eight months gene therapy currently requires, and transplant should be pursued instead.
Are biological parents automatically half-match donors, and what are the realistic chances of finding a match within the immediate family?▼
Parents are usually a half match by default, provided they are not sicklers themselves and have no disqualifying condition such as HIV or organ damage. A full-match sibling occurs in about 25% of cases, and a half-matched sibling is actually a better donor than a half-matched parent, since sibling cells are better tolerated with fewer pre-existing antibody reactions. Beyond parents and siblings, more distant relatives such as aunts, uncles or cousins are rarely even a half match, so realistic donor availability is mostly limited to the immediate family.
Can adults present with dactylitis?▼
Dactylitis, swelling of the fingers from small vessel blockage in the hands, is more commonly seen in children because they have not yet developed collateral blood vessels the way adults have. In adults, the vessels involved are relatively larger and better able to develop collaterals, so dactylitis is much less common in that age group.
For a positive diagnosis, is the hemoglobin S level the same across all countries?▼
Patients carrying both sickle cell genes typically have a haemoglobin S level above 60%, and below that the manifestations are usually milder, seen more in sickle cell trait or a combination haemoglobinopathy such as HbSC or HbSE. There is a general tendency for higher HbS to mean more symptoms, but the correlation is not exact and cannot be relied on mathematically for any individual patient.
What types of stroke are sickle cell patients most likely to suffer from, and how can it be prevented?▼
The middle and posterior cerebral artery territories are affected most commonly, similar to the pattern seen in adults, though the anterior territory can occasionally be involved too. Regular transcranial Doppler screening from two years of age is the key prevention tool: it uses ultrasound to measure blood flow velocity in the cerebral vessels and identifies children at higher risk of stroke early, so that preventive medication and closer monitoring can begin before a stroke actually happens.
What are the main indications for bone marrow transplant in sickle cell disease?▼
A history of stroke, two or more episodes of acute chest syndrome, transfusion dependence, more than three hospital visits for painful crises in a year, and evidence of cardiomyopathy or tricuspid valve regurgitation on screening.
What is engraftment and why is it the most critical step in a bone marrow transplant?▼
Engraftment is when the donor's stem cells reach the patient's bone marrow and begin producing healthy blood cells, usually within two to three weeks. It is the step transplant physicians watch most closely, since the steps before it rarely cause complications.
In This Series: Diagnosis and Management of Sickle Cell Disease
- 1.Diagnosis and Management of Sickle Cell Disease
- 2.Understanding Sickle Cell Disease: Genetics and Pathophysiology
- 3.Recognizing the Symptoms and Complications of Sickle Cell Disease
- 4.Stroke Risk and Screening in Sickle Cell Disease
- 5.Diagnosing Sickle Cell Disease: Screening and Prenatal Testing
- 6.Supportive Care and Pharmacological Treatment for Sickle Cell Disease
- 7.Bone Marrow Transplant for Sickle Cell Disease: Indications and Process
- 8.Finding a Donor Match for Bone Marrow Transplant in Sickle Cell Disease
- 9.Bone Marrow Transplant Complications and Post-Transplant Monitoring
- 10.Gene Therapy for Sickle Cell Disease: CRISPR Editing and Gene Addition
- 11.Sickle Cell Disease in Pregnancy